Community Pharmacy Bjelovar, Bjelovar, Croatia.
University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia.
Eur J Clin Nutr. 2022 Dec;76(12):1675-1681. doi: 10.1038/s41430-022-01189-0. Epub 2022 Aug 4.
Constipation is one of the most common gastrointestinal conditions, particularly among older individuals. This study aimed to evaluate the efficacy and safety of selected multistrain probiotics on functional constipation and laboratory blood parameters in the elderly living in a nursing home.
Sixty participants (42 females and 18 males) aged 77.9 ± 8.84 years with functional constipation, who met the eligibility criteria, completed the study. In a double-blind, placebo-controlled, parallel design, each participant was randomized to receive either the selected probiotic mixture (N = 28) or placebo (N = 32) for 12 weeks as an adjunct to their usual diet and medications. The liquid probiotic formulation containing Bifidobacterium animalis subsp. lactis BLC1, Lactobacillus acidophilus LA3 and Lactobacillus casei BGP93 was tested for the first time.
Supplementation of selected probiotics resulted in a slight but nonsignificant increase in cumulative stool frequency compared with placebo. However, after the 71st day of the treatment, the cumulative number of stools was significantly higher in the probiotic group (P < 0.05) when the influence of laxative was excluded. The trend towards an increase in the difference between the two groups, which began 1 week after the probiotic intervention, pointed out to their prolonged effect. There were no significant dependent or independent effects of treatment and time on most of the 27 laboratory blood parameters tested.
Multistrain probiotic supplementation was found to be efficacious, safe and well tolerated in the elderly with functional constipation.
便秘是最常见的胃肠道疾病之一,尤其在老年人中更为常见。本研究旨在评估特定多菌株益生菌对养老院中老年人功能性便秘和实验室血液参数的疗效和安全性。
60 名符合条件的参与者(42 名女性和 18 名男性),年龄 77.9±8.84 岁,患有功能性便秘,完成了这项研究。在一项双盲、安慰剂对照、平行设计中,每位参与者随机接受选定的益生菌混合物(N=28)或安慰剂(N=32),作为其常规饮食和药物治疗的辅助治疗,为期 12 周。含有动物双歧杆菌亚种 lactis BLC1、嗜酸乳杆菌 LA3 和干酪乳杆菌 BGP93 的液体益生菌配方是首次进行测试。
与安慰剂相比,补充特定益生菌略微但无统计学意义地增加了累积粪便频率。然而,在治疗的第 71 天,当排除泻药的影响时,益生菌组的累积粪便次数明显更高(P<0.05)。这种趋势表明,从益生菌干预后第 1 周开始,两组之间的差异开始增加,表明其具有延长的效果。在测试的 27 个实验室血液参数中,大多数参数没有治疗和时间的显著依赖性或独立性影响。
在患有功能性便秘的老年人中,多菌株益生菌补充剂被发现是有效、安全且耐受良好的。